Apoptotic markers in cancer

被引:107
作者
Holdenrieder, S [1 ]
Stieber, P [1 ]
机构
[1] Univ Hosp Munich Grosshadern, Inst Clin Chem, D-81377 Munich, Germany
关键词
cell death; apoptosis; cancer; tumor; diagnosis; prognosis; therapy; monitoring; prediction; sFas; CD95; cytokeratins; CYFRA; 21-1; TPA; TPS; DNA; nucleosomes;
D O I
10.1016/j.clinbiochem.2004.05.003
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
In cancer, apoptotic processes occur both spontaneously and induced by antitumor therapies. Qualitative and quantitative changes in cancer cell death along with proliferative alterations are essential determinants in the pathogenesis and progression of malignant disease and its responsiveness to therapy. Besides detecting apoptosis by invasive means in tumor tissue, apoptotic products can be quantified in the circulation. Although circulating apoptotic products usually lack organ and tumor specificity, they contribute in the assessment of disease extent or aggressiveness. The ease of drawing blood facilitates the serial measurement of circulating apoptotic markers to monitor antitumor treatment and predict early response to therapy. This review describes the features of apoptotic and necrotic cell death along with the role the balance between the rates of cell death and cell proliferation plays in the progression of malignancy. The intracellular pathways mediating apoptosis are next summarized. The focus then shifts to the apoptotic markers found in the circulation and their diagnostic, prognostic, predictive, and management utility in cancer. (C) 2004 The Canadian Society of Clinical Chemists. All rights reserved.
引用
收藏
页码:605 / 617
页数:13
相关论文
共 192 条
[1]   The Bcl-2 protein family: Arbiters of cell survival [J].
Adams, JM ;
Cory, S .
SCIENCE, 1998, 281 (5381) :1322-1326
[2]   Detecting lung cancer in plasma with the use of multiple genetic markers [J].
Andriani, F ;
Conte, D ;
Mastrangelo, T ;
Leon, M ;
Ratcliffe, C ;
Roz, L ;
Pelosi, G ;
Goldstraw, P ;
Sozzi, G ;
Pastorino, U .
INTERNATIONAL JOURNAL OF CANCER, 2004, 108 (01) :91-96
[3]   Circulating nucleic acids in plasma and serum as a noninvasive investigation for cancer: Time for large-scale clinical studies? [J].
Anker, P ;
Mulcahy, H ;
Stroun, M .
INTERNATIONAL JOURNAL OF CANCER, 2003, 103 (02) :149-152
[4]   Tumor-related alterations in circulating DNA, potential for diagnosis, prognosis and detection of minimal residual disease [J].
Anker, P ;
Stroun, M .
LEUKEMIA, 2001, 15 (02) :289-291
[5]  
Aotake T, 1999, CLIN CANCER RES, V5, P135
[6]  
ARENDS MJ, 1990, AM J PATHOL, V136, P593
[7]   Death receptors: Signaling and modulation [J].
Ashkenazi, A ;
Dixit, VM .
SCIENCE, 1998, 281 (5381) :1305-1308
[8]  
Ayude D, 2003, ONCOL REP, V10, P1345
[9]   Cutting edge communication -: Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation [J].
Bewick, M ;
Conlon, M ;
Parissenti, AM ;
Lee, H ;
Zhang, L ;
Glück, S ;
Lafrenie, RM .
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2001, 10 (06) :759-768
[10]  
Bodenmueller Heinz, 1994, International Journal of Biological Markers, V9, P75